Oncimmune Holdings Future Growth
Future criteria checks 2/6
Oncimmune Holdings is forecast to grow earnings and revenue by 100.9% and 105.1% per annum respectively while EPS is expected to grow by 32% per annum.
Key information
100.9%
Earnings growth rate
32.0%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 105.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 21 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 8/31/2025 | 7 | 0 | -1 | -1 | 1 |
| 8/31/2024 | 3 | -3 | -4 | -3 | 1 |
| 2/29/2024 | 1 | -3 | -6 | -5 | N/A |
| 11/30/2023 | 1 | -5 | -6 | -6 | N/A |
| 8/31/2023 | 1 | -6 | -7 | -7 | N/A |
| 8/31/2022 | 2 | -5 | -6 | -5 | N/A |
| 5/31/2022 | 3 | -10 | -7 | -6 | N/A |
| 2/28/2022 | 4 | -8 | -7 | -6 | N/A |
| 11/30/2021 | 3 | -7 | -7 | -5 | N/A |
| 8/31/2021 | 4 | -6 | -6 | -5 | N/A |
| 5/31/2021 | 4 | -5 | -6 | -5 | N/A |
| 2/28/2021 | 3 | -5 | -6 | -6 | N/A |
| 11/30/2020 | 2 | -6 | -7 | -7 | N/A |
| 8/31/2020 | 1 | -7 | -8 | -8 | N/A |
| 5/31/2020 | 1 | -8 | -9 | -9 | N/A |
| 2/29/2020 | 0 | -9 | -9 | -9 | N/A |
| 11/30/2019 | 0 | -9 | -9 | -9 | N/A |
| 8/31/2019 | 0 | -9 | -8 | -8 | N/A |
| 5/31/2019 | 0 | -8 | -8 | -7 | N/A |
| 2/28/2019 | 0 | -8 | -7 | -7 | N/A |
| 11/30/2018 | 0 | -7 | -7 | -7 | N/A |
| 8/31/2018 | 0 | -7 | -7 | -6 | N/A |
| 5/31/2018 | 0 | -6 | -6 | -6 | N/A |
| 2/28/2018 | 0 | -6 | -6 | -6 | N/A |
| 11/30/2017 | 0 | -5 | N/A | -5 | N/A |
| 8/31/2017 | 0 | -5 | N/A | -5 | N/A |
| 5/31/2017 | 0 | -5 | N/A | -4 | N/A |
| 2/28/2017 | 0 | -8 | N/A | -4 | N/A |
| 11/30/2016 | 0 | -10 | N/A | -5 | N/A |
| 8/31/2016 | 0 | -9 | N/A | -4 | N/A |
| 5/31/2016 | 0 | -8 | N/A | -3 | N/A |
| 5/31/2015 | 1 | -2 | N/A | -2 | N/A |
| 5/31/2014 | 1 | -1 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OCY is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OCY is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OCY is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OCY's revenue (105.1% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: OCY's revenue (105.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OCY's Return on Equity is forecast to be high in 3 years time